In April 2024, a crowd gathered around an exhibition booth at the Zhongguancun Forum in Beijing. On the screen, a monkey moved a robotic arm, picked up a strawberry, and brought it to its mouth. No joystick. No buttons. Thought alone. The video was released by the Beijing Institute for Brain Research and its subsidiary, NeuCyber NeuroTech. China's state news agency Xinhua reported it as China's first high-performance invasive brain-computer interface. Three years after Neuralink's monkey Pager played Pong, China had moved to the stage of interacting with the physical world.

If Silicon Valley's innovations started in garages and grew on the fuel of venture capital, China's innovations are assembled on blueprints drawn by the state. That blueprint has a name: the China Brain Project. This massive plan is not a science experiment. It is China's national survival strategy for an era when the brain becomes a new battlefield and data becomes the new oil.

A. The China Brain Project and State-Led BCI Research

In March 2016, the 13th Five-Year Plan was announced at the Great Hall of the People in Beijing. Buried in the thousands of pages, Western intelligence analysts spotted an item that caught their attention: five characters reading "brain science and brain-inspired intelligence technology." China had designated this field a core national strategic priority. It was Beijing's answer to the BRAIN Initiative that the Obama administration had launched in 2013. When the United States declared it would pour $3 billion into mapping the brain, China harbored a larger ambition. They would not stop at understanding the brain. They would fuse it with artificial intelligence and turn it into a weapon of national competitiveness.

The structure of the China Brain Project is summed up in four Chinese characters: yi ti liang yi, or "one body, two wings." The body refers to the neurological understanding of human cognitive function: the fundamental exploration of how we remember, how we make decisions, how we feel emotions. The two wings point to the diagnosis and treatment of brain diseases on one side, and the development of brain-inspired artificial intelligence on the other. Where the United States placed its emphasis on basic science, China put applications and commercialization at the center of its design from the very start. To them, BCI was not a medical device. It was a platform technology.

This difference shows up in how the money flows. Under a program called Science and Technology Innovation 2030, the Chinese government allocated a budget in the trillions of won for brain science research. Research hubs were established in Beijing and Shanghai. In 2018, the Beijing municipal government and several universities jointly founded the Chinese Institute for Brain Research, known by its English acronym CIBR. It became the vanguard of this strategy. Neuralink had been founded in San Francisco roughly two years earlier.

Dr. Luo Minmin, who took on the role of CIBR's inaugural director, is a figure who embodies China's BCI strategy. He earned his PhD in neuroscience at the University of Pennsylvania and spent nearly a decade in the United States. Then he returned to his homeland. In an interview with CNN, he was candid: the United States is still

the leader in both invasive and non-invasive approaches. But he saw something else. China had millions of patients desperate to participate in clinical trials. Stroke, spinal cord injury, ALS. The demand was overwhelming.

In July 2025, the Chinese government released a policy document titled "Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry." Signed jointly by multiple ministries, including the Ministry of Science and Technology, the Ministry of Industry and Information Technology, and the National Health Commission, the document laid out explicit goals: achieve breakthrough advances in core technologies by 2027, and cultivate two to three leading enterprises with global influence by 2030. BCI was no longer a laboratory experiment. It had risen to the ranks of national strategic industries, alongside semiconductors and electric vehicles.

七部门关于推动脑机接口产业创新发展的实施意见

工业和信息化部 国家发展改 委 教育部 国家卫 健康委 国务院国资委 中国科学院 国家药监局关于推动脑机接 产业创新发展的实施意见

Brain-computer interface technology builds information channels between the brain and machines, enabling collaborative interaction between biological intelligence and machine intelligence. It is a frontier technology at the convergence of life sciences and information sciences. Currently, innovative BCI achievements continue to emerge, the industry is growing rapidly, and disruptive breakthroughs are taking shape. BCI has already become a critical domain where scientific and industrial innovation converge deeply. To seize the opportunities presented by the new wave of scientific and industrial transformation, promote high-quality development of the BCI industry, accelerate the formation of new productive forces, empower new-type industrialization at a high level, and support the construction of a modern industrial system, these implementation opinions are hereby formulated.

By 2027, breakthroughs will be achieved in core BCI technologies, and an advanced technology system, industrial system, and standards system will be preliminarily established. The performance of electrodes, chips, and finished products will reach internationally advanced levels, and BCI products will accelerate their application in industrial manufacturing, healthcare, and consumer life. The industrial scale will continue to expand, two to three industrial development clusters will be established, and new scenarios, new models, and new business formats will be pioneered.

By 2030, the BCI industry's innovation capacity will be significantly improved, and a safe and reliable industrial system will take shape. Two to three leading enterprises with global influence and a number of specialized and innovative small and medium-sized enterprises will be cultivated. An internationally competitive industrial ecosystem will be built, and overall strength will advance into the world's top tier.

Implantable electrodes targeting different regions, including epidural, subdural, and intracortical areas, will be developed. Cerebrovascular interventional electrodes will be explored, and material stability and reliability will be strengthened. Dedicated fabrication and packaging processes will be developed to improve electrode channel count, biocompatibility, spatial resolution, and signal-to-noise ratio. Development of non-implantable electrodes with high availability and adaptive self-adjustment will be accelerated. New electrode materials with low impedance and thin dielectric layers will be advanced to improve electrode convenience, comfort, and ease of use.

High-channel, high-speed brain signal acquisition chips will be developed. Analog-to-digital conversion, channel management, and noise suppression will be strengthened to improve brain signal acquisition and amplification capability. High-performance, ultra-low-power brain signal processing chips will be developed. Parallel processing capability will be strengthened, and integration of sensing, computing, and modulation functions into a single unit will be promoted.

Brain signal encoding and decoding software will be refined. Cognitive load during the encoding process will be reduced. Artificial intelligence techniques will be applied to strengthen decoding capability and task iteration optimization, improving encoding and decoding accuracy, response speed, and scenario versatility.

New products integrating high-density neural recording sensors and ultra-low-power implantable chips will be explored, with innovations in brain intent recognition to improve control precision and response speed. New product forms, including forehead-mounted, ear-mounted, in-ear, and hair-clip types, will be created, pushing non-implantable products toward lighter weight, higher speed, and lower power consumption. Integrated BCI products such as helmets, head-mounted displays, glasses, and headphones will be developed. By converging with existing consumer products, these efforts will support iterative application and mass adoption of non-implantable products.

High-precision surgical robots based on implantable BCI will be developed, achieving breakthroughs in sub-micron-level precision control and dynamic adjustment technology, and improving capabilities in regional precise real-time imaging and three-dimensional reconstruction.

Leading enterprises in the BCI sector will be developed and grown. They will be supported in forming industrial innovation consortia and taking the lead on major national science and technology projects. Innovation supply from small and medium-sized BCI enterprises will be promoted. Cultivation of specialized and innovative SMEs, "little giant" enterprises, and unicorn companies will be accelerated, driving integrated innovation across large, medium, and small enterprises.

A BCI technical standards system will be established, a standardization development roadmap will be laid out, and active participation in international standard-setting will be pursued to promote China's standards internationally.

Ethics research will be continuously promoted. A governance system featuring cross-departmental coordination and public participation will be established to ensure that technological innovation and scientific ethics develop in harmony. A data governance framework will be created to regulate the collection, storage, and use of user information, prevent brain privacy leaks, and improve the security of biological and digital information.

Key Summary

Brain-computer interface is a technology that builds information channels between the brain and machines, enabling collaborative interaction between biological intelligence and machine intelligence. It stands at the cutting edge where life sciences and information sciences converge. BCI innovation results continue to emerge, the industry is accelerating its growth and incubating disruptive breakthroughs, and it has already become a critical domain where scientific and industrial innovation are deeply fused. These implementation opinions are formulated to seize the opportunities of the new scientific and industrial revolution, promote high-quality development of the BCI industry, accelerate the formation of new productive forces, empower new-type industrialization at a high level, and provide strong support for building a modern industrial system.

By 2027, breakthroughs will be achieved in core BCI technologies, and an advanced technology system, industrial system, and standards system will be preliminarily established. Electrode, chip, and finished product performance will reach internationally advanced levels, and BCI products will accelerate their application in industrial manufacturing, healthcare, and consumer life. The industrial scale will continue to expand, two to three industrial development clusters will be created, and new scenarios, new models, and new business formats will be pioneered.

By 2030, the BCI industry's innovation capacity will be significantly improved, and a safe and reliable industrial system will take shape. Two to three leading enterprises with global influence and a number of specialized and innovative SMEs will be cultivated. An internationally competitive industrial ecosystem will be built, and overall strength will advance to the world's top tier.

Implantable electrodes targeting different regions, including epidural, subdural, and intracortical areas, will be developed. Cerebrovascular interventional electrodes will be explored, and material stability and reliability will be strengthened. Dedicated fabrication and packaging processes will be developed to improve electrode channel count, biocompatibility, spatial resolution, and signal-to-noise ratio. Development of non-implantable electrodes with high availability and adaptive self-adjustment will be accelerated. New electrode materials with low impedance and thin dielectric layers will be advanced to improve electrode convenience, comfort, and ease of use.

High-channel, high-speed brain signal acquisition chips will be developed. Analog-to-digital conversion, channel management, and noise suppression will be strengthened to improve brain signal acquisition and amplification capability. High-performance, ultra-low-power brain signal processing chips will be developed. Parallel processing capability will be strengthened, and the integration of sensing, computing, and modulation functions into a single unit will be promoted.

The plan calls for completing brain signal encoding-decoding software, reducing the cognitive load of the encoding process, and applying artificial intelligence to improve decoding accuracy and optimize task iteration. The goals include raising encoding-decoding precision, response speed, and scenario versatility.

The roadmap envisions new products that integrate high-density neural recording sensors with ultra-low-power implantable chips, advancing brain-intent recognition to improve control precision and response speed. Product form factors will be diversified: forehead-mounted, ear-mounted, in-ear, and hairpin-style devices. Non-invasive products are to become lighter, faster, and lower in power consumption. Integrated BCI products combining helmets, head-mounted displays, glasses, and earphones will be developed, merging with existing consumer electronics to support iterative application and large-scale adoption of non-invasive devices.

High-precision surgical robots for implantable BCIs are to be developed, achieving breakthroughs in sub-micron precision control and dynamic adjustment, while improving regional real-time imaging and three-dimensional reconstruction capabilities.

Leading BCI enterprises are to be cultivated, with support for forming industrial innovation alliances and taking the lead in national major science and technology projects. Innovation by small and medium BCI enterprises will be encouraged, accelerating the development of 'specialized, refined, distinctive, and novel' SMEs, 'little giant' firms, and unicorn companies, while promoting integrated innovation across companies of all sizes.

A BCI technology standards system is to be established, with a standardization development roadmap. China will actively participate in international standards development and aggressively promote the adoption of Chinese standards overseas.

Ethics research will be pursued on an ongoing basis, building a governance framework with inter-ministerial coordination and public participation to ensure that technological innovation and scientific ethics advance in harmony. A data governance framework is to be established, regulating the collection, storage, and use of user information, preventing brain-privacy leaks, and strengthening the protection of biometric digital information.

(End of China's regulatory provisions.)

Local governments jumped in competitively. In January 2025, Beijing released its own BCI development action plan, declaring it would cultivate three to five unicorn companies by 2027. Shanghai issued a similar plan the same month. Guangdong Province classified BCI as a life-and-health future industry and committed to intensive

support. In 2024 alone, 484 BCI-related patents were filed in Beijing. Guangdong followed with 360, and Tianjin with 294.

What these numbers tell us is clear. China sees BCI not as a medical technology but as a test of national capability. University basic research, hospital clinical data, and corporate commercialization are connected in a single pipeline. The cycle from a Beijing lab developing a technology, to a Shanghai hospital running clinical trials, to a Shenzhen factory producing a finished product is startlingly short. That is the power of a state-driven model.

American researchers are aware of this. In 2024, a team at Georgetown University published a report on China's BCI progress. They wrote: China's non-invasive BCI research has reached parity with scientifically advanced nations. Invasive research, historically behind its non-invasive counterpart, is also accelerating and approaching global standards. An eight-year gap had shrunk to fifteen months.

Yet this enormous machine casts shadows. The strategy known as civil-military fusion deliberately erases the boundary between civilian and military technology. Some Western analysts worry that China's BCI research could be applied to cognitive augmentation of soldiers or to controlling unmanned aircraft. Dr. Luo Minmin denied this. 'Our technology has nothing to do with the military. We are focused on helping paralyzed patients.' Whether his words represent the full truth, or only the truth he is permitted to share publicly, is impossible to know.

What is certain is this: the China Brain Project carries the label of scientific research, but its essence is a matter of national competitiveness. The goal is to decode the language of the brain, but what sentences that language will write remains undecided. They could be sentences of healing. They could be sentences of surveillance. Or they could be sentences we have not yet imagined.

B. Beijing Xinzhida (NeuCyber) NeuroTechnology's Rehabilitation Solutions

On a morning in March 2025, a 67-year-old woman in a ward at Beijing Xuanwu Hospital stared at a computer screen. She was an ALS patient. She had lost her voice long ago. Her lips did not move. But four characters appeared on the screen: 'I want to eat.' Written in Chinese, the sentence had come directly from her brain.

What made this scene possible was a coin-sized chip. Called BeiNao-1, the device is a semi-invasive BCI co-developed by the Beijing Institute of Brain Science and NeuCyber NeuroTechnology. NeuCyber's controlling shareholder is the Zhongguancun Development Group, a Beijing municipal state-owned enterprise that recorded revenues of 9 billion yuan, roughly 1.7 trillion Korean won, in 2023. Referred to in international media as Beijing Xinzhida NeuroTechnology, the organization effectively straddles the line between state and private enterprise.

BeiNao-1's technical approach differs from Neuralink's. Neuralink inserts electrodes deep into brain tissue. Signal quality is high, but so is surgical risk. BeiNao-1 places its chip on top of the dura mater, the outermost of three membranes encasing the brain. Because it does not penetrate brain tissue directly, the risks of bleeding and infection are reduced. Signal precision is lower in exchange. But Dr. Luo Minmin did not see this as purely a disadvantage. He said: 'The two products are not competitors. Comparing them is like comparing apples and oranges.'

Maximilian Riesenhuber, a neuroscientist at Georgetown University, agreed. He told CNN: 'It is interesting that NeuCyber can obtain enough information through the dura to decode specific words. This is important data demonstrating the potential of semi-invasive technology.'

By May 2025, BeiNao-1 had been implanted in a total of five patients. Dr. Luo said he planned to implant it in thirteen more by the end of the year. His goal for 2026 was to obtain regulatory approval and conduct a formal clinical trial with fifty participants. If realized, BeiNao-1 would become the BCI system with the largest patient dataset in the world. Synchron currently has ten patients and Neuralink has three.

The clinical results were encouraging. A 38-year-old male patient surnamed Dong, paralyzed from the neck down after a traffic accident in 2020, had felt nothing below his neck for years. One year after receiving the BeiNao system, he could pick up small objects. He could grip a pen. Partial bowel control returned. For the first time in four years, he sweated during rehabilitation training. This was not a technology demonstration. It was a moment when a human life changed.

NeuCyber did not stop there. They are developing BeiNao-2, a fully invasive chip. In monkey experiments, this chip successfully achieved precise control of a robotic arm. Dr. Luo estimated that a wireless version of BeiNao-2 would be tested in humans within twelve to eighteen months. This product will compete directly with Neuralink's N1.

The core of the BeiNao system as a rehabilitation solution lies in closed-loop feedback. When a patient thinks about moving an arm, the BCI detects the intention. The signal is transmitted to an external device that activates a robotic arm or exoskeleton suit. At the same time, a functional electrical stimulation device sends electrical signals to the patient's muscles, causing them to contract. Repeated cycles of this process strengthen the neural connections between brain and muscles. It is rehabilitation training that exploits the brain's plasticity.

China has a market that desperately needs this technology. It is one of the countries with the highest stroke rates in the world. Millions of patients live with motor impairments. Existing rehabilitation infrastructure falls far short of demand. BCI-based rehabilitation systems have the potential to fill this gap. In March 2025, Hubei Province became the first in China to publish medical reimbursement rates for BCI procedures. The cost of invasive BCI implantation was set at 6,552 yuan, roughly 1.2 million Korean won. Non-invasive BCI fitting was priced at 966 yuan. This means BCI is moving beyond the experimental stage and into the medical system.

NeuCyber is not the only player in China. Shanghai-based NeuroXess is developing flexible electrode technology using silk protein. In January 2025, the company announced that during a language-decoding clinical trial, a patient thought the sentence 'Happy New Year' and the computer successfully decoded it. Neuracle, collaborating with Tsinghua University, has developed a minimally invasive system called NEO and plans to apply it to epilepsy and stroke rehabilitation. The company announced large-scale clinical trials involving thirty to fifty spinal cord injury patients in 2025.

Investment is pouring in. In February 2025, Shanghai-based StairMed raised 350 million yuan, about 65 billion Korean won, the largest funding round in China's invasive BCI sector. Yet this amount remains small compared to the $649 million Neuralink secured in June 2024. In terms of capital scale, the American advantage persists.

Dr. Luo Minmin acknowledges this point. But he emphasizes different strengths: the speed of patient recruitment, an integrated research-clinical-industry network, and government backing. After news of BeiNao-1's clinical trials spread, countless patients reached out for help, he said. That demand is the most powerful engine driving technology development.

The rise of Beijing Xinzhida and NeuCyber shows that BCI technology is not the exclusive domain of Silicon Valley. They are combining China's manufacturing capacity with abundant clinical resources to build an independent ecosystem. Competition is not decided by technology alone. It is a systems fight that includes patient recruitment, hospital partnerships, regulatory approval, manufacturing, and cost structure. And in that fight, China is a formidable competitor.

C. The BCI Market Explosion: From Medical Devices to the Neuro-Consumer Market

One day in 2024, a strange sight was spotted at an elementary school in Hangzhou. Students sat in class wearing bands around their heads. The bands measured brainwaves and monitored concentration in real time. Green for focused, red for distracted. Each student's attention level appeared as a color on the teacher's tablet. In any Western country, this experiment would have been shut down immediately over privacy concerns. But in China, where academic ambition and competition run deep, it was accepted as a scientific learning management tool.

This is one snapshot of the neuro-consumer era. BCI technology is leaving the hospital and entering everyday life, not through invasive implants but through wearable devices like headbands, earbuds, and glasses.

According to the market research firm Precedence Research, the global brain technology market was worth roughly $2.6 billion in 2024. It is projected to grow to $12.4 billion by 2034. China's market alone is expected to expand from $85.5 million in 2024 to $242 million by 2030, a compound annual growth rate of 19.3%.

Two forces are driving this explosion.

The first is the evolution of non-invasive technology. The electrodes needed for brainwave measurement have gotten smaller and cheaper. Dry electrode technology has arrived, eliminating the hassle of applying conductive gel. AI-based signal processing algorithms filter out noise and extract meaningful patterns.

Smartphones and the cloud connect all of it. The second force is the expansion of applications. It's not just medicine anymore. Wellness, education, gaming, and industrial safety are all areas where BCI is making inroads.

The wellness market is at the front of the line. A brand called Muse makes a meditation headband that measures brainwaves and gives users feedback on their mental state. When you focus, you hear birdsong; when your mind wanders, you hear wind and rain. The Master & Dynamic MW75 Neuro headphones hide EEG sensors inside the ear cushions and adjust audio based on cognitive state. Emotiv's MN8 earbuds measure brainwaves from inside the ear. Products like these poured out of CES 2025.

The sleep market is enormous too. Companies including BrainCo have released smart eye masks that analyze brainwaves during sleep and play sounds at specific frequencies to induce deeper rest.

For young Chinese professionals ground down by punishing work schedules, the pitch of hacking your brain to improve the quality of rest is irresistible. Neurofeedback apps promising stress management and better focus are filling up app stores.

BCI is being used in industrial settings as well. A company called Entertech attaches brainwave sensors to the helmets of miners and truck drivers to measure fatigue levels. When the risk of drowsy driving is detected, an alarm sounds.

Chinese state-owned enterprises have adopted the system. Under the banner of safety, workers' brainwaves are monitored in real time. Where is the line between efficiency and surveillance?

The gaming industry is also becoming a catalyst for BCI.

Valve's Gabe Newell has been working with OpenBCI to explore game interfaces controlled by brain signals. An immersive experience where difficulty adjusts to your concentration and the game environment shifts with your emotional state. At ChinaJoy, the gaming expo in Shanghai, BCI games that let players trigger character skills with thought alone were demonstrated. Snap acquired NextMind, a non-invasive BCI startup, and folded it into its AR research. BCI is evolving into a next-generation input device.

The entry of Big Tech companies is heating up this market even more. Apple has filed a patent for embedding brainwave measurement capabilities into AirPods. The earbuds that hundreds of millions of people wear every day could become a conduit to the brain. Mood-aware computing, where a device detects your stress level and recommends music or adjusts notifications, is going mainstream. Samsung is building a biometric signal ecosystem by linking Galaxy Buds and the Galaxy Ring.

Meta is more radical. Mark Zuckerberg unveiled a wrist-worn electromyography band. The band intercepts neural signals traveling from the brain to the hand. Users can click and scroll without physically moving their fingers. Combined with augmented reality glasses, it completes an interface for manipulating the digital world with thought alone. This is the fourth input method, after the keyboard and mouse, and the touchscreen.

Chinese companies are zeroing in on the education market. BrainCo's focus headband is an FDA-cleared consumer product. They have expanded operations to Hong Kong, targeting education and rehabilitation at the same time. Their promise is to boost learning efficiency by analyzing students' brainwaves. But this carries the risk of turning classrooms into spaces of surveillance.

The growth of the neuro-consumer market raises new ethical questions. When companies collect not just our click data but also our emotions, attention levels, and unconscious preferences, how can mental privacy be protected? UNESCO adopted neuroethics standards in 2025. This reflects a growing international consensus that brain data must be treated as its own category.

Yet regulation cannot keep pace with technology. In 2024, the Chinese government issued ethical guidelines for BCI research, laying out principles such as informed consent, personal data protection, and safeguards for vulnerable populations. Still,

under the pressure to grow the industry, it is difficult for regulation to stay ahead of commercialization. The neuro-consumer market is both a technological opportunity and a test of how humanity will protect its most intimate space: the mind.

The market explosion is not happening because invasive implants are about to go mainstream. It is driven by a cycle: low-risk sensors combined with AI and apps inflate the market from the outside as neuro-consumer products, and the attention and capital they generate flow back into medical and clinical research. Some forecasts put the Chinese BCI market at 120 billion yuan, roughly 22 trillion Korean won, by 2040. The age of the neuro-economy is opening.

D. The Patent War: 2,160 Patent Families and 664 Companies in Competition

Another war is being waged outside the laboratory. Fought in law offices and patent bureaus, this war matters more than published papers and will outlast clinical trials. It is a patent war. To claim technology standards first and block competitors from entering, companies are building dense patent barriers. The name of that barrier is the moat.

According to a recent report by PatentVest, a patent analytics firm, 3,336 individual patent applications worldwide in the BCI field are classified into 2,160 unique patent families. The number of organizations that filed these patents reaches 664. It is not just commercial companies. Universities and research institutes account for a significant share. Seventy-seven percent of these patents are currently active or under examination, while 23% have expired or been abandoned.

What do these numbers tell us? That BCI is not a field dominated by a handful of giants. Universities and research institutes lay a broad base of foundational patents, while startups and large corporations layer application-level patents tightly on top. PatentVest's analysis shows that universities, including Tianjin University, hold a large share of foundational innovation. Stanford and the University of California system do as well. Academic institutions hold the original technology, and companies build commercialization patents on that foundation.

The U.S.-China rivalry sits at the heart of this war. In quantitative terms, the United States still holds the lead. Neuralink has filed 56 patents, 18 of which have been granted. It has secured key patents in electrode insertion robotics, flexible electrode threads, and wireless charging and data transmission technologies. Blackrock Neurotech has built a formidable defensive line with its decades-old Utah Array patent portfolio. Synchron has deployed a patent strategy spanning 10 countries and formed a partnership with Nvidia.

China's pace of pursuit, though, is alarming. In recent years, China has ranked first in the world for the rate of increase in BCI-related patent filings. More than 100 patents are issued per year. A Chinese company called Ping An Technology holds over 100 neurotech patents, making it the world's second-largest patent holder in the field after IBM. This reflects China's view of BCI as a platform technology that can be fused with finance, healthcare, insurance, and other industries.

The two countries' patent strategies differ in character. The United States focuses on foundational technology: electrode materials, brain signal decoding methods, implant communication protocols, the kind of technologies that form the skeleton of a BCI system.

China competes on volume in the applied and non-invasive domains. Patents are concentrated on technologies ready for immediate commercialization, things like drowsy driving prevention systems using brainwaves, emotion recognition algorithms, and rehabilitation robot control methods. This is an encirclement strategy. If you can't overtake the foundational technology head-on, seize the initiative at the application layer.

PatentBest's analysis reveals one more interesting point: the segmentation strategies of major companies. Firms like Neuralink, Synchron, Precision Neuroscience, and Paradromics are each targeting their own technical niches rather than competing head-on. Neuralink focuses on surgical automation and fully invasive precision. Synchron builds its patent portfolio around its unique endovascular delivery method. Paradromics concentrates on ultra-high-bandwidth data transmission, while Precision zeroes in on surface-mounted brain films. This signals that the BCI market will not follow a winner-take-all structure but will evolve into a landscape where multiple technologies coexist.

Patent data also shows where the technology is heading. Recent filings have moved beyond simple signal measurement toward brain-cloud interfaces and AI-driven neural modulation. Systems that transmit brainwave data to the cloud, where AI analyzes it in real time and delivers feedback. Or algorithms where AI learns the brain's signal patterns and decodes the user's intentions with increasing accuracy. The competition has shifted from who can read the brain better to who can merge the brain and AI more completely.

Big Tech's entry is reshaping the landscape. Apple, Google, Microsoft, and Meta have been filing patents in large numbers to integrate biosignal processing into their existing wearable devices. They are racing to stake out the technical chokepoints for turning smart glasses, earbuds, and smartwatches into BCI devices. Their strategy is to seize platform control when BCI goes mainstream. Just as it happened with smartphones, platforms, not hardware, may decide the winner in BCI.

The race over international standards is heating up as well. International standards bodies like ISO are actively working to establish BCI data formats and safety criteria. China announced a medical device standard called YY/T 1987-2025, set to take effect in January 2026. Behind the scenes, an invisible diplomatic contest is unfolding between the United States and China, each trying to register its own technology as the international standard.

Whoever wins the patent war, one thing is clear. The human brain has moved beyond being an object of discovery; it is now an object of invention and of ownership. The 2,160 patent families are not just technical documents. They are title deeds staking out the territory of a future society where brains and computers are connected. We are

witnessing, for the first time in human history, an era in which intellectual property rights over the ability to think are being defined.

In this war, whoever lays down the broadest scope of rights first determines which products live and which die. Building a smarter decoder is not enough. You need the right to sell that decoder freely. That is why companies produce as many documents in their legal departments as experiments in their labs. While scientists decode the language of neurons, lawyers draft the language of rights. Both languages shape the future.